# David B. Solit

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/david-b-solit/

## Facts

| Field | Value |
| --- | --- |
| Citations | 86,915 |
| Field | Cancer Genomics and Diagnostics |
| h-index | 142 |
| i10-index | 396 |
| Last Known Institution | Memorial Sloan Kettering Cancer Center |
| OpenAlex ID | https://openalex.org/A5102710156 |
| ORCID iD | https://orcid.org/0000-0002-6614-802X |
| Works | 1,832 |

## Researcher papers

Showing 12 of 29.

- [Tumor mutational load predicts survival after immunotherapy across multiple cancer types](https://scholariq.org/papers/tumor-mutational-load-predicts-survival-after-immunotherapy-across-multiple/)
- [Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients](https://scholariq.org/papers/mutational-landscape-of-metastatic-cancer-revealed-from-prospective-clinical/)
- [OncoKB: A Precision Oncology Knowledge Base](https://scholariq.org/papers/oncokb-a-precision-oncology-knowledge-base/)
- [AACR Project GENIE: Powering Precision Medicine through an International Consortium](https://scholariq.org/papers/aacr-project-genie-powering-precision-medicine-through-an-international/)
- [Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer](https://scholariq.org/papers/inherited-dna-repair-gene-mutations-in-men-with-metastatic-prostate-cancer/)
- [Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing](https://scholariq.org/papers/molecular-determinants-of-response-to-anti-programmed-cell-death-pd-1-and-anti/)
- [BRAF mutation predicts sensitivity to MEK inhibition](https://scholariq.org/papers/braf-mutation-predicts-sensitivity-to-mek-inhibition/)
- [Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy](https://scholariq.org/papers/patient-hla-class-i-genotype-influences-cancer-response-to-checkpoint-blockade/)
- [The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers](https://scholariq.org/papers/the-genomic-landscape-of-endocrine-resistant-advanced-breast-cancers/)
- [Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer](https://scholariq.org/papers/tumor-evolution-and-drug-response-in-patient-derived-organoid-models-of-bladder/)
- [Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes](https://scholariq.org/papers/therapy-related-clonal-hematopoiesis-in-patients-with-non-hematologic-cancers-is/)
- [High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants](https://scholariq.org/papers/high-intensity-sequencing-reveals-the-sources-of-plasma-circulating-cell-free/)

## Researcher topics

- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Bladder and Urothelial Cancer Treatments](https://scholariq.org/topics/bladder-and-urothelial-cancer-treatments/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Esophageal Cancer Research and Treatment](https://scholariq.org/topics/esophageal-cancer-research-and-treatment/)

## Researcher university

- [Memorial Sloan Kettering Cancer Center](https://scholariq.org/institutions/memorial-sloan-kettering-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.